Telix's Prostate Cancer Imaging Agent Clears Key Hurdle in China
Event summary
- Chinese NMPA accepted the New Drug Application for Telix's Illuccix prostate cancer imaging agent on January 19, 2026.
- The submission includes data from a Phase 3 study showing 94.8% positive predictive value for tumor detection.
- Over two-thirds of patients experienced treatment plan changes based on Illuccix imaging results.
- Telix submitted the application with its partner Grand Pharmaceutical Group for the Greater China region.
The big picture
This NDA acceptance marks Telix's first regulatory filing in China, a strategically important market with over 134,000 prostate cancer diagnoses in 2022 and growing at 6% annually. The submission comes as China expands access to nuclear medicine, with PET/CT installations surpassing 1,600 by the end of 2025. Illuccix's success in China could validate its position as a global standard in prostate cancer imaging, competing with conventional methods like bone scans and CT scans.
What we're watching
- Regulatory Timeline
- The pace at which NMPA will grant final approval for Illuccix in China.
- Market Penetration
- How Telix and Grand Pharma will leverage China's growing PET/CT infrastructure to commercialize the product.
- Clinical Impact
- Whether the high positive predictive value demonstrated in Chinese patients will translate into broader adoption across Asia.
Related topics